AU1194501A - Inhibition of tumorigenic properties of melanoma cells - Google Patents

Inhibition of tumorigenic properties of melanoma cells

Info

Publication number
AU1194501A
AU1194501A AU11945/01A AU1194501A AU1194501A AU 1194501 A AU1194501 A AU 1194501A AU 11945/01 A AU11945/01 A AU 11945/01A AU 1194501 A AU1194501 A AU 1194501A AU 1194501 A AU1194501 A AU 1194501A
Authority
AU
Australia
Prior art keywords
inhibition
melanoma cells
tumorigenic properties
tumorigenic
properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11945/01A
Inventor
Meenhard Herlyn
Kapaettu Satyamoorthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of AU1194501A publication Critical patent/AU1194501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
AU11945/01A 1999-10-14 2000-10-11 Inhibition of tumorigenic properties of melanoma cells Abandoned AU1194501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15935399P 1999-10-14 1999-10-14
US60159353 1999-10-14
PCT/US2000/027953 WO2001026643A1 (en) 1999-10-14 2000-10-11 Inhibition of tumorigenic properties of melanoma cells

Publications (1)

Publication Number Publication Date
AU1194501A true AU1194501A (en) 2001-04-23

Family

ID=22572230

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11945/01A Abandoned AU1194501A (en) 1999-10-14 2000-10-11 Inhibition of tumorigenic properties of melanoma cells

Country Status (2)

Country Link
AU (1) AU1194501A (en)
WO (1) WO2001026643A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5368798B2 (en) 2005-10-31 2013-12-18 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosing and treating cancer
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
WO2012010675A2 (en) 2010-07-21 2012-01-26 Universite Montpellier 2 Sciences Et Techniques Bhlh proteins and their use as drugs
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (en) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with WNT pathway inhibitors
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5976837A (en) * 1997-03-14 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AU742365B2 (en) * 1997-03-14 2002-01-03 Selective Genetics, Inc. Adenoviral vectors with modified tropism
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses

Also Published As

Publication number Publication date
WO2001026643A9 (en) 2002-05-10
WO2001026643A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
AU5743200A (en) Protection of communications
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU3867400A (en) Methods of using bioelastomers
AU4395100A (en) Highly branched polycondensates
AU6330199A (en) Electrochemical synthesis of perfluoroalkylfluorophosphoranes
AU5729300A (en) Electrophoresis-assisted staining of materials
AU5235299A (en) Spectral topography of mammalian matter
AU1488501A (en) Methods of inhibiting metastasis
AU6115400A (en) Antisense modulation of mekk5 expression
AU6564600A (en) Copolymers of acryloyloxyalkylamino compounds
AU1194501A (en) Inhibition of tumorigenic properties of melanoma cells
AU6690300A (en) Copolymers of acryloylaminoalkyl compounds
AU7792900A (en) Distribution of certifiers
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU5486700A (en) Antisense modulation of g-alpha-s1 expression
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
AU4369000A (en) Inhibition of complement action
AU1082701A (en) Short segments of dap-kinase
AU2026801A (en) Melanin synthesis inhibition compound and composition containing the same
AU2410600A (en) Antisense modulation of g-alpha-i3 expression
AU5874800A (en) Antisense modulation of ets-2 expression
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
AU5615700A (en) Antisense modulation of g-alpha-i2 expression
AU1489701A (en) Antisense modulation of nck-2 expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase